SoFi Technologies Soars 6.6% Amid Mixed Earnings Today; UPS Plunges 10.6%

Generated by AI AgentWord on the Street
Tuesday, Jul 29, 2025 5:05 pm ET1min read
Aime RobotAime Summary

- Wall Street opened lower after mixed earnings, with the Dow and Nasdaq down 0.5%-0.4% following record highs.

- SoFi Technologies surged 6.6% while UPS plunged 10.6% and Merck fell 1.7%, highlighting divergent stock performances.

- The Fed began a rate meeting amid calls for cuts, but markets expect no immediate action without stronger economic data.

- UnitedHealth Group dropped 7.5% after missing spring earnings and issuing a weak 2025 profit forecast below $16/share.

- Novo Nordisk shares fell 21.8% after cutting growth forecasts and tempering Wegovy drug expectations, while AI-driven Cadence Design Systems rose nearly 10%.

Wall Street's trading week started with a pullback after recent record highs, as the juggernaut earnings season provided a mixed bag of corporate results. A broad spectrum of U.S. companies disclosed their performance from the past quarter. The Dow Jones Industrial Average declined 204 points, or 0.5%, and the Nasdaq Composite trimmed 0.4%, following a period of successive record closes.

Socitech company

posted a robust gain of 6.6% in its stock, which contrasted with other major players that faced setbacks. Notably, (UPS) suffered a steep decline of 10.6% following its profit report, while saw its shares drop by 1.7%.

Amid a week that is poised to deliver forecasts on corporate profits and economic indicators, the Federal Reserve initiated a two-day meeting to discuss interest rate directions. Despite calls for reduced rates, the prevailing assumptions suggest that the Federal Reserve will hold off on adjustments pending further economic data.

Amid these developments,

experienced a stock decline of 7.5% after disclosing a financial performance that fell short of market expectations for the spring. Furthermore, the company provided a profit outlook for 2025 that investors found less favorable, with a forecast of earnings no greater than $16 per share, which failed to meet the analysts' expectations of around $20.

Danish pharmaceutical giant

, facing competitive pressures, revised its growth forecast for sales, leading to a 21.8% slide in its U.S.-listed shares. The adjustments were partly attributed to tempered expectations for their Wegovy weight-loss drug. Additionally, the company announced the appointment of a new CEO.

Cadence Design Systems stood out positively, enjoying a nearly 10% rise in its shares. The software firm credited its advancement to the burgeoning investments in artificial intelligence, leading to an upward revision in its revenue projections for the year.

International markets presented varied performances. Japan's Nikkei Index dropped 0.8%, while several Asian and European indices advanced.

The week's financial narrative is accentuated by ongoing evaluations of corporate earnings, which provide a pivotal gauge for investor sentiment amid evolving economic landscapes and policy considerations.

Comments



Add a public comment...
No comments

No comments yet